Clinical Trial

A Trial of HRS-4508 Combined With Other Antitumor Therapies in Subjects With Locally Advanced or Metastatic Non-small Cell Lung Cancer

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The study is being conducted to evaluate the efficacy, safety, and ORR of HRS-4508 combined with other antitumor therapies in subjects with locally advanced or metastatic non-small cell lung cancer; Evaluate the pharmacokinetic (PK) characteristics of HRS-4508 and other efficacy endpoints for the treatment of locally advanced or metastatic non-small cell lung cancer.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-11-14.
Status change: Not Yet Recruiting → Recruiting 2025-12-11
Trial Details
NCT Number NCT07232849
Lead Sponsor Jiangsu HengRui Medicine Co., Ltd.
Conditions Lung Cancer
Enrollment 100 participants
Start Date 2025-12-04
Primary Completion 2027-12 (estimated)
Study Completion 2028-12 (estimated)
Updated on ClinicalTrials.gov 2025-12-12